Eletriptan vs sumatriptan: A double-blind, placebo-controlled, multiple migraine attack study

G. Sandrini, M. Färkkilä, G. Burgess, E. Forster, S. Haughie

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Objective: To compare the efficacy of oral eletriptan, 40 mg and 80 mg, and oral sumatriptan, 50 mg and 100 mg, in the acute treatment of migraine. Methods: Patients with a history of migraine (n = 1,008) were randomly assigned to receive placebo, 40 mg of eletriptan, 80 mg of eletriptan, 50 mg of sumatriptan, or 100 mg of sumatriptan to treat up to three attacks. Early headache response (at 1 hour) was the primary endpoint, in addition to the standard endpoint, 2-hour headache response. Results: Headache response rates were 12% at 1 hour and 31% at 2 hours for placebo; 24% at 1 hour and 50% at 2 hours for sumatriptan 50 mg; 27% at 1 hour and 53% at 2 hours for sumatriptan 100 mg; 30% at 1 hour and 64% at 2 hours for eletriptan 40 mg; and 37% at 1 hour and 67% at 2 hours for eletriptan 80 mg. More patients receiving eletriptan 80 mg achieved a 1-hour headache response than did patients receiving sumatriptan 50 mg (p <0.05). All doses of eletriptan were superior to sumatriptan at 2 hours for headache response and complete pain relief (p <0.05). Significantly more patients on eletriptan 80 mg achieved headache response in all attacks than did patients receiving either sumatriptan dose. Eletriptan 40 mg was superior to both sumatriptan doses in functional improvement (p <0.005). The superior efficacy of both eletriptan doses was associated with higher rates of patient acceptability than sumatriptan 50 mg (p <0.05). Eletriptan and sumatriptan were well tolerated. Conclusion: Oral eletriptan (40 mg and 80 mg) is effective, safe, and tolerable in the acute treatment of migraine and yields a consistent response.

Original languageEnglish
Pages (from-to)1210-1217
Number of pages8
JournalNeurology
Volume59
Issue number8
Publication statusPublished - Oct 22 2002

Fingerprint

Sumatriptan
Migraine Disorders
Placebos
Headache
eletriptan

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Sandrini, G., Färkkilä, M., Burgess, G., Forster, E., & Haughie, S. (2002). Eletriptan vs sumatriptan: A double-blind, placebo-controlled, multiple migraine attack study. Neurology, 59(8), 1210-1217.

Eletriptan vs sumatriptan : A double-blind, placebo-controlled, multiple migraine attack study. / Sandrini, G.; Färkkilä, M.; Burgess, G.; Forster, E.; Haughie, S.

In: Neurology, Vol. 59, No. 8, 22.10.2002, p. 1210-1217.

Research output: Contribution to journalArticle

Sandrini, G, Färkkilä, M, Burgess, G, Forster, E & Haughie, S 2002, 'Eletriptan vs sumatriptan: A double-blind, placebo-controlled, multiple migraine attack study', Neurology, vol. 59, no. 8, pp. 1210-1217.
Sandrini G, Färkkilä M, Burgess G, Forster E, Haughie S. Eletriptan vs sumatriptan: A double-blind, placebo-controlled, multiple migraine attack study. Neurology. 2002 Oct 22;59(8):1210-1217.
Sandrini, G. ; Färkkilä, M. ; Burgess, G. ; Forster, E. ; Haughie, S. / Eletriptan vs sumatriptan : A double-blind, placebo-controlled, multiple migraine attack study. In: Neurology. 2002 ; Vol. 59, No. 8. pp. 1210-1217.
@article{3c63c5a51b71459e9fe7e31399899e0e,
title = "Eletriptan vs sumatriptan: A double-blind, placebo-controlled, multiple migraine attack study",
abstract = "Objective: To compare the efficacy of oral eletriptan, 40 mg and 80 mg, and oral sumatriptan, 50 mg and 100 mg, in the acute treatment of migraine. Methods: Patients with a history of migraine (n = 1,008) were randomly assigned to receive placebo, 40 mg of eletriptan, 80 mg of eletriptan, 50 mg of sumatriptan, or 100 mg of sumatriptan to treat up to three attacks. Early headache response (at 1 hour) was the primary endpoint, in addition to the standard endpoint, 2-hour headache response. Results: Headache response rates were 12{\%} at 1 hour and 31{\%} at 2 hours for placebo; 24{\%} at 1 hour and 50{\%} at 2 hours for sumatriptan 50 mg; 27{\%} at 1 hour and 53{\%} at 2 hours for sumatriptan 100 mg; 30{\%} at 1 hour and 64{\%} at 2 hours for eletriptan 40 mg; and 37{\%} at 1 hour and 67{\%} at 2 hours for eletriptan 80 mg. More patients receiving eletriptan 80 mg achieved a 1-hour headache response than did patients receiving sumatriptan 50 mg (p <0.05). All doses of eletriptan were superior to sumatriptan at 2 hours for headache response and complete pain relief (p <0.05). Significantly more patients on eletriptan 80 mg achieved headache response in all attacks than did patients receiving either sumatriptan dose. Eletriptan 40 mg was superior to both sumatriptan doses in functional improvement (p <0.005). The superior efficacy of both eletriptan doses was associated with higher rates of patient acceptability than sumatriptan 50 mg (p <0.05). Eletriptan and sumatriptan were well tolerated. Conclusion: Oral eletriptan (40 mg and 80 mg) is effective, safe, and tolerable in the acute treatment of migraine and yields a consistent response.",
author = "G. Sandrini and M. F{\"a}rkkil{\"a} and G. Burgess and E. Forster and S. Haughie",
year = "2002",
month = "10",
day = "22",
language = "English",
volume = "59",
pages = "1210--1217",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Eletriptan vs sumatriptan

T2 - A double-blind, placebo-controlled, multiple migraine attack study

AU - Sandrini, G.

AU - Färkkilä, M.

AU - Burgess, G.

AU - Forster, E.

AU - Haughie, S.

PY - 2002/10/22

Y1 - 2002/10/22

N2 - Objective: To compare the efficacy of oral eletriptan, 40 mg and 80 mg, and oral sumatriptan, 50 mg and 100 mg, in the acute treatment of migraine. Methods: Patients with a history of migraine (n = 1,008) were randomly assigned to receive placebo, 40 mg of eletriptan, 80 mg of eletriptan, 50 mg of sumatriptan, or 100 mg of sumatriptan to treat up to three attacks. Early headache response (at 1 hour) was the primary endpoint, in addition to the standard endpoint, 2-hour headache response. Results: Headache response rates were 12% at 1 hour and 31% at 2 hours for placebo; 24% at 1 hour and 50% at 2 hours for sumatriptan 50 mg; 27% at 1 hour and 53% at 2 hours for sumatriptan 100 mg; 30% at 1 hour and 64% at 2 hours for eletriptan 40 mg; and 37% at 1 hour and 67% at 2 hours for eletriptan 80 mg. More patients receiving eletriptan 80 mg achieved a 1-hour headache response than did patients receiving sumatriptan 50 mg (p <0.05). All doses of eletriptan were superior to sumatriptan at 2 hours for headache response and complete pain relief (p <0.05). Significantly more patients on eletriptan 80 mg achieved headache response in all attacks than did patients receiving either sumatriptan dose. Eletriptan 40 mg was superior to both sumatriptan doses in functional improvement (p <0.005). The superior efficacy of both eletriptan doses was associated with higher rates of patient acceptability than sumatriptan 50 mg (p <0.05). Eletriptan and sumatriptan were well tolerated. Conclusion: Oral eletriptan (40 mg and 80 mg) is effective, safe, and tolerable in the acute treatment of migraine and yields a consistent response.

AB - Objective: To compare the efficacy of oral eletriptan, 40 mg and 80 mg, and oral sumatriptan, 50 mg and 100 mg, in the acute treatment of migraine. Methods: Patients with a history of migraine (n = 1,008) were randomly assigned to receive placebo, 40 mg of eletriptan, 80 mg of eletriptan, 50 mg of sumatriptan, or 100 mg of sumatriptan to treat up to three attacks. Early headache response (at 1 hour) was the primary endpoint, in addition to the standard endpoint, 2-hour headache response. Results: Headache response rates were 12% at 1 hour and 31% at 2 hours for placebo; 24% at 1 hour and 50% at 2 hours for sumatriptan 50 mg; 27% at 1 hour and 53% at 2 hours for sumatriptan 100 mg; 30% at 1 hour and 64% at 2 hours for eletriptan 40 mg; and 37% at 1 hour and 67% at 2 hours for eletriptan 80 mg. More patients receiving eletriptan 80 mg achieved a 1-hour headache response than did patients receiving sumatriptan 50 mg (p <0.05). All doses of eletriptan were superior to sumatriptan at 2 hours for headache response and complete pain relief (p <0.05). Significantly more patients on eletriptan 80 mg achieved headache response in all attacks than did patients receiving either sumatriptan dose. Eletriptan 40 mg was superior to both sumatriptan doses in functional improvement (p <0.005). The superior efficacy of both eletriptan doses was associated with higher rates of patient acceptability than sumatriptan 50 mg (p <0.05). Eletriptan and sumatriptan were well tolerated. Conclusion: Oral eletriptan (40 mg and 80 mg) is effective, safe, and tolerable in the acute treatment of migraine and yields a consistent response.

UR - http://www.scopus.com/inward/record.url?scp=0037159234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037159234&partnerID=8YFLogxK

M3 - Article

C2 - 12391349

AN - SCOPUS:0037159234

VL - 59

SP - 1210

EP - 1217

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 8

ER -